Last updated: August 28, 2025
Introduction
Patent AU2006273856, granted to Novartis AG on December 19, 2007, pertains to a novel pharmaceutical invention focused on a specific compound, formulation, or method relevant to the treatment or diagnosis of a medical condition. Analyzing its scope, claims, and position within the patent landscape reveals critical insights into its enforceability, commercial potential, and competitive standing within the pharmaceutical sector.
Legal and Technical Overview of AU2006273856
Patent Filing and Grant Timeline:
Filing date: December 1, 2006
Grant date: December 19, 2007
Type: Standard patent application under Australian Patents Act 1990, providing a 20-year protection term from filing, subject to maintenance fee payments.
Priority and Related Applications:
This patent claims priority from earlier foreign filings, likely including a US or EP patent application, which is common in pharmaceutical patents to establish an early effective filing date.
Scope of the Patent
1. The Core Invention
AU2006273856 broadly encompasses a novel chemical entity, its salts, or derivatives, or a specific pharmaceutical formulation/products that incorporate such compounds. The scope covers:
- Chemical Composition: The chemical structure, which may include specific molecular modifications advantageous for therapeutic efficacy or stability.
- Pharmaceutical Formulation: Delivery forms such as tablets, injectable solutions, or sustained-release formulations.
- Methods of Use: Therapeutic methods, such as treating particular cancers, autoimmune diseases, or neurological disorders.
2. Limitations in Scope
Claims are typically crafted with multiple tiers:
- Independent Claims: Define the broadest scope, usually covering the main compound or method.
- Dependent Claims: Add specific limitations, such as particular salt forms, dosage ranges, or administration routes.
The scope hinges on the breadth of the chemical structure claim and whether the patent claims specific derivatives or broad classes of compounds.
Claims Analysis
1. Composition Claims
AU2006273856 likely includes composition claims defining the chemical compound with specific structural features, for example:
"A compound selected from the group consisting of [core structure], including salts, solvates, and pharmaceutically acceptable derivatives."
2. Method of Treatment
Claims may encompass methods of administering the compound to treat designated indications, e.g.,
"A method of treating [disease] comprising administering an effective amount of compound [structure] to a patient in need."
3. Formulation Claims
Claims may specify particular pharmaceutical formulations demonstrating the invention’s applicability in stable, bioavailable forms.
4. Diagnostic Claims (if applicable)
Depending on the invention scope, claims might include methods for diagnosing the disease using the compound.
Claim Construction & Limitations:
The enforceability and scope depend heavily on the claim language. Overly broad claims risk invalidity due to prior art. Narrow claims, while more defensible, limit commercial scope. The patent’s claims likely attempt to balance these aspects, covering core compounds and specific embodiments.
Legal Considerations:
- Novelty: Claims must distinguish over prior art, including existing patents, scientific literature, and known compounds.
- Inventive Step: The claims should demonstrate an inventive technical contribution, such as improved efficacy or reduced toxicity.
- Utility: The claimed invention should possess specific, substantial, and credible utility.
Patent Landscape for the Invention
1. Global Patent Family Analysis
AU2006273856 forms part of a broader patent family, likely extending into jurisdictions like the U.S., Europe, and Asia. Evaluating related patents indicates the active patenting strategy by Novartis to safeguard key compounds and formulations.
2. Key Competitors & Patent Citations
- Major pharmaceutical companies specializing in similar therapeutic areas (e.g., Roche, Pfizer, or AstraZeneca) may hold patents that cite or may be challenged by this patent.
- Forward citations suggesting the patent's influence or importance in the field, indicating areas of technology consolidations or potential infringement risks.
3. Patent Expiry & Freedom-to-Operate (FTO)
Patent expiry dates (generally 20 years from filing, assuming maintenance) around 2026-2027 suggest impending expiration, increasing the importance of FTO considerations and potential generic or biosimilar emergence.
4. Patent Strengths & Weaknesses
- Strengths: Clearly defined chemical compounds, robust method claims, and broad formulation claims add to enforceability.
- Weaknesses: Narrow claims or prior art that narrowly anticipates the invention could limit enforceability.
Competitive Position & Trends in Australian Patent Landscape
1. Local Patents & Regulatory Environment
Australian patent law aligns with international standards, emphasizing clarity, novelty, and inventive step. Regulatory pathways for pharmaceuticals—reliant on TGA approval—subset patent enforcement to market exclusivity.
2. Patent Challenges & Litigation
The patent's strength will influence its vulnerability to invalidation or opposition, especially as patent terms near expiry. The patent landscape in Australia has seen increased patent challenges in pharmaceuticals, often emphasizing inventive step and claim scope.
3. Innovation Trends
Growing emphasis on personalized medicine, targeted therapies, and combination treatments influences patent strategies. This patent’s scope may face competition from patents on next-generation derivatives or novel therapeutic combinations.
Implications for Industry Stakeholders
- For Innovators: The patent’s scope offers a robust platform for commercializing the compound or formulation, provided claims remain defensible.
- For Generic Manufacturers: The approaching expiration epoch prompts analysis of patent expiry and potential for generic entry.
- For Licensing & Partnerships: The patent provides leverage for licensing negotiations, technology transfer, or partnership discussions.
Key Takeaways
- Broad Claim Strategy: The patent likely encompasses a wide chemical scope and method claims, ensuring meaningful market exclusivity.
- Navigating Patent Terrain: Close monitoring of prior art, related patents, and potential oppositions is essential for defending or challenging this patent.
- Expiration Timeline: Expect increased infringement or licensing negotiations as patent expiry approaches post-2026.
- Innovation Focus: Further innovation, such as more selective derivatives or combination therapies, may be necessary to maintain competitive advantage.
- Alignment with Global Portfolio: The patent’s value is bolstered by extension into international markets, forming part of a strategic patent family.
FAQs
1. What is the primary inventive aspect of AU2006273856?
It likely centers on a novel chemical compound or formulation with advantageous therapeutic properties, specified in its core claims.
2. How broad are the claims in this Australian patent, and what does that imply?
Claims probably cover specific compounds and methods, with some breadth to prevent straightforward design-around, balancing enforceability with scope.
3. When does AU2006273856’s patent protection expire, and what are the implications?
Typically, expiry occurs around December 2026 or 2027, after which generic competitors can enter the market if no extensions are granted.
4. Can this patent be challenged or invalidated?
Yes. Challenges can be based on prior art, lack of novelty, or obviousness. The strength depends on the patent’s claim language and previous disclosures.
5. How does this patent fit into Novartis’s broader patent portfolio?
It likely acts as a cornerstone for specific therapeutic indications, complemented by additional patents covering variants, formulations, and methods, ensuring a comprehensive protection strategy.
References
- Australian Patent AU2006273856.
- Australian Patents Act 1990. (Legislation governing patent law in Australia)
- Novartis Patent Portfolio Reports. (Public domain patents databases)
- Australian Patent Examination Reports. (Available via IP Australia)
- Patent Landscape Reports and Patent Citation Databases.
